Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer

The 5-year survival rate for individuals with surgically resected, early-stage non-small cell lung cancer (NSCLC) is around 50%. Recent availability of biomarker-driven therapy after surgery offers the promise of improved outcomes. However, current gaps in the quality of diagnostic evaluation, delivery of evidence-based treatment, coordination of care, and availability of biomarker testing remain barriers to optimal outcomes.